Kupando GmbH
Wolfram Nothaft, MD, currently serves as Head of Asset Leadership at AbbVie since September 2024 and also holds the position of Deputy Chair of the Board at Kupando GmbH since May 2021. Prior experience includes Chief Medical Officer and Executive Vice President at Takeda from January 2019 to September 2024, and various leadership roles at Shire from December 2012 to January 2019, including Head of Global Clinical Development. Previous positions also encompass leadership roles in global pharmaceutical research at Abbott, Astellas Pharma US, Takeda Europe R&D Centre, and Hoechst Marion Roussel. Wolfram Nothaft earned a medical degree from FAU Erlangen-Nürnberg, completing an Internal Medicine Residency Program.
This person is not in any teams
This person is not in any offices
Kupando GmbH
Kupando is a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. The Company uses its small molecule-based drug candidates to build a pipeline in several indications, in-house or via strategic partnerships, as single agent, or in combination with checkpoint inhibitors, other drugs or antigens. Its drug candidate KUP101 is the only TLR 4/7 agonist in development and consists of two small molecules, TLR4 agonist and TLR7 agonist, co-encapsulated. IND-enabling work is on-going for treatment of solid tumors and prophylaxis of infectious diseases. Kupando is a private company, seed financed by its CEO Johanna Holldack and based on technology invented by Dennis Carson’s Laboratory at the University of California San Diego. The Company’s management team brings a unique wealth of experience in business and drug development, gained in the US and Europe. Kupando is headquartered in Schoenefeld, Germany.